Skip to content

Haemonetics HAE Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Abbott logo
AbbottABT
TFX
TeleflexTFX
Boston Scientific logo
Boston ScientificBSX
Medtronic logo
MedtronicMDT
LivaNova logo
LivaNovaLIVN
ICU Medical logo
ICU MedicalICUI

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's deferred tax assets and other non-current assets?
Haemonetics (HAE) reported deferred tax assets and other non-current assets of $141.74M in Q1 2026.
How has Haemonetics's deferred tax assets and other non-current assets changed year-over-year?
Haemonetics's deferred tax assets and other non-current assets decreased by 13.6% year-over-year, from $164.11M to $141.74M.
What is the long-term trend for Haemonetics's deferred tax assets and other non-current assets?
Over 5 years (2021 to 2026), Haemonetics's deferred tax assets and other non-current assets has grown at a 14.9% compound annual growth rate (CAGR), from $70.88M to $141.74M.